Français | English

Agence nationale sanitaire et scientifique en cancérologie

Accueil Nota Bene Cancer V2 Numéro 134 du 03 Mai 2012 Traitements Fiche de publication

Imprimer

Nota Bene Cancer Fiche de publication

Updated Results and Patterns of Failure in a Randomized Hypofractionation Trial for High-risk Prostate Cancer

Mené sur 168 patients atteints d'un cancer de la prostate présentant un risque élevé de récidive (durée médiane de suivi : 70 mois), cet essai randomisé de phase III compare, du point de vue de la récidive biochimique, locale ou distante, l'efficacité à long terme et les facteurs clinicopathologiques d'échec d'une radiothérapie conventionnelle fractionnée et d'une radiothérapie hypofractionnée combinée à un traitement anti-androgénique

  • International journal of radiation oncology, biology, physics, sous presse, 2012 (résumé)

Résumé en anglais :
To report long-term results and patterns of failure after conventional and hypofractionated radiation therapy in high-risk prostate cancer. This randomized phase III trial compared conventional fractionation (80 Gy at 2 Gy per fraction in 8 weeks) vs hypofractionation (62 Gy at 3.1 Gy per fraction in 5 weeks) in combination with 9-month androgen deprivation therapy in 168 patients with high-risk prostate cancer. Freedom from biochemical failure (FFBF), freedom from local failure (FFLF), and freedom from distant failure (FFDF) were analyzed. In a median follow-up of 70 months, biochemical failure (BF) occurred in 35 of the 168 patients (21%) in the study. Among these 35 patients, local failure (LF) only was detected in 11 (31%), distant failure (DF) only in 16 (46%), and both LF and DF in 6 (17%). In 2 patients (6%) BF has not yet been clinically detected. The risk reduction by hypofractionation was significant in BF (10.3%) but not in LF and DF. We found that hypofractionation, with respect to conventional fractionation, determined only an insignificant increase in the actuarial FFBF but no difference in FFLF and FFDF, when considering the entire group of patients. However, an increase in the 5-year rates in all 3 endpoints—FFBF, FFLF, and FFDF—was observed in the subgroup of patients with a pretreatment prostate-specific antigen (iPSA) level of 20 ng/mL or less. On multivariate analysis, the type of fractionation, iPSA level, Gleason score of 4+3 or higher, and T stage of 2c or higher have been confirmed as independent prognostic factors for BF. High iPSA levels and Gleason score of 4+3 or higher were also significantly associated with an increased risk of DF, whereas T stage of 2c or higher was the only independent variable for LF. Our results confirm the isoeffectiveness of the 2 fractionation schedules used in this study, although a benefit in favor of hypofractionation cannot be excluded in the subgroup of patients with an iPSA level of 20 ng/mL or less. The α/β ratio might be more appropriately evaluated by FFLF than FFBF results, at least in high-risk disease.

NBC n° 134 du 03 Mai 2012

Mots clés : Prostate; Traitements (Combinaison de traitements localisés et systémiques)

Recherche de publications

Recherche avancée

Widget

 

Archives

Formulaire d’abonnement

Pour recevoir gratuitement chaque nouveau numéro de Nota Bene Cancer par courriel :

S'abonner

Sources

Pour visualiser l'ensemble des sources alimentant le Nota Bene Cancer :

Accéder au portail des sources du NBC

Foire aux questions

Pour trouver les réponses aux questions que vous vous posez sur Nota Bene Cancer :

Accéder à la F.A.Q.